Apogee's safety trial of APG777+APG990 vs Dupixent nears H2 2026 readout
The fully enrolled Phase 1b study will report adverse-event rates against Dupixent, a tolerability test, not an efficacy verdict, for Apogee's atopic dermatitis combination.
Executive Summary
- Apogee has finished enrolling a head-to-head safety comparison of its APG777+APG990 combination against Dupixent in atopic dermatitis, and the trial is now closed to new patients while it runs toward its primary completion date.
- The registered primary endpoint measures adverse-event rates, not skin-clearance or itch outcomes, so the upcoming readout will speak to tolerability of combining two biologics rather than to comparative efficacy.
- Enrollment grew during the study and the trial converted to Active, not recruiting at target, a pattern consistent with normal execution rather than any distress signal.
- No competitor trial in atopic dermatitis shares Apogee's mechanism, leaving this combination without a mechanism-matched precedent in the current field even as multiple approved and late-stage therapies compete on established biology.
The trial
The study, registered as NCT07027527, is an active-comparator safety trial pitting the APG777+APG990 combination against Dupilumab (marketed as Dupixent) in adults with moderate-to-severe atopic dermatitis. Enrollment reached 86 patients and the trial moved to Active, not recruiting status on March 25, 2026, after recruitment ran from June 2025 through that date. The trial sites are in Australia, Canada, and New Zealand. NCT07027527An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisNCT07027527
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What it measures
The registered primary endpoint is the number of participants with treatment-emergent adverse events, a safety measure, and the trial carries six secondary pharmacokinetic endpoints tracking peak and trough serum concentrations of both antibodies. No efficacy endpoint, such as an Eczema Area and Severity Index or Investigator's Global Assessment score, sits among the trial's registered outcomes. That design means the readout Apogee has guided for the second half of 2026 will establish whether adding APG990 to APG777 changes the adverse-event profile relative to an approved biologic, not whether the combination clears skin disease better than Dupixent. NCT07027527An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisNCT07027527
The operational path
The trial's enrollment target rose from 50 to 80 patients in December 2025 and then to 86 in March 2026, alongside a primary completion date that moved from October 1, 2026 to December 1, 2026. An operational risk model built to flag disproportionate enrollment swings treats this pattern as within the routine band for a Phase 1 study, since Phase 1 enrollment increases are excluded from its threshold for a flagged change. The trial filled to its final target and is now closed to new patients, consistent with a study proceeding on schedule rather than one showing signs of abandonment or dormancy. NCT07027527An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisNCT07027527
The guidance record
Apogee has repeated the same H2-2026 readout window across nine separate disclosures dating back to its December 2, 2024 R&D Day, when it first outlined plans for a Phase 1b head-to-head trial of the combination against Dupixent. At that R&D Day, Chief Executive Officer Michael Henderson said the company aimed to demonstrate "enhanced efficacy and best-in-class dosing for patients" by combining APG777 with APG990. The trial dosed its first patient in July 2025, and the guided window has held constant through each subsequent update, including as recently as May 2026. ApogeeApogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs ...Dec 2, 2024
The competitive field
Atopic dermatitis carries an established set of approved biologics and oral therapies competing on already-validated mechanisms, and none of the trials identified in the broader competitive field share Apogee's target or mechanism class. That leaves APG777+APG990 without a mechanism-matched comparator in atopic dermatitis specifically. Apogee is separately running a Phase 2 monotherapy trial of APG777 in the same indication, which the company has said informs its multi-wave strategy of combining APG777 with APG990 and, in respiratory disease, with APG333. ApogeeApogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs ...Dec 2, 2024
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.